ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+18.68%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$224M
AUM Growth
–
Cap. Flow
+$224M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
57.17%
Holding
159
New
150
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Royalty Pharma
RPRX
|
$37.1M |
| 2 |
Keros Therapeutics
KROS
|
$27.4M |
| 3 |
Roivant Sciences
ROIV
|
$14.1M |
| 4 |
Arbutus Biopharma
ABUS
|
$8.67M |
| 5 |
Cytokinetics
CYTK
|
$7.69M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 85.9% |
| 2 | Technology | 1.4% |
| 3 | Financials | 1.4% |
| 4 | Materials | 1.24% |
| 5 | Consumer Staples | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Altimmune
ALT
$338M
| – | – |
0
| – | – |
|
152
Arvinas
ARVN
$568M
| – | – |
0
| – | – |
|
|
BCLI
153
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| – | – |
0
| – | – |
|
154
EyePoint Pharmaceuticals
EYPT
$797M
| – | – |
0
| – | – |
|
155
Madrigal Pharmaceuticals
MDGL
$9.76B
| – | – |
0
| – | – |
|
156
RAPT Therapeutics
RAPT
$188M
| – | – |
0
| – | – |
|
157
Reviva Pharmaceuticals
RVPH
$30.6M
| – | – |
0
| – | – |
|
158
Rhythm Pharmaceuticals
RYTM
$6.85B
| – | – |
0
| – | – |
|
159
Soleno Therapeutics
SLNO
$3.6B
| – | – |
0
| – | – |
|